RegMed Investors’ (RMi) pre-open: scary markets out-there, careful as you go

March 4, 2022 8:48am

Attention is focused on the war on Ukraine as a huge Ukraine nuclear power plant was on fire while being seized by Russian troops. Zaporizhzhia is the largest nuclear power plant in Europe and one of the world's 10 largest.

Investors will also turn their attention to Friday's jobs report, due out before the stock market open

Pre-open indications: 4 SELLs indications, 3 BUYs Indication and 1 pimp/pump/promote

RMi outlines a daily bell weather of “indications” about what you need to know; it’s what could happen or materialize after the opening and what might happen during the session.

Only the facts … I ask questions and note the indications of what could happen …

Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.

Dow futures are DOWN -0.61% (-207 points), S&P futures are DOWN -0.62% (-27 points) and NASDAQ futures are DOWN -0.52% (-73 points)

Stock futures fell early Friday as worrisome developments in Ukraine weighed on sentiment as investors kept an eye toward the latest reading on the jobs market,

European markets retreated as the pan-European Stoxx 600 slid 2.5%,

Asia-Pacific markets were lower with MSCI’s broadest index of Asia-Pacific shares outside Japan declined 1.48%.

Henry’omics:

The situation in Ukraine is rapidly deteriorating …

From last night’s post, “Indexes fell on Thursday but, started to re-climb at 12;30 p.m. as markets slowed and investors monitored the war in Ukraine. The moves come after a volatile start to the week, with markets seeing sharp reversals in some sectors.”

Thursday was an “outside” day for the Nasdaq, with means its intraday range exceeded Wednesday's highs and lows. Outside days are more meaningful. So, the downside reversal was even more discouraging. <IBD>

Economic Data Docket: key jobs report

·         The Labor Department released its February jobs report Friday at 8:30 a.m. ET. Here were the main metrics from the print, compared to consensus estimates compiled by Bloomberg:

·         Non-farm payrolls: +678,000 vs. +423,000 expected and an upwardly revised +481,000 in January

·         Unemployment rate: 3.8% vs. 3.9% expected, 4.0% in January

·         Average hourly earnings, month-over-month: 0.0% vs. 0.5% expected and a downwardly revised 0.6% in January

·         Average hourly earnings, year-over-year: 5.1% vs. 5.8% expected and a downwardly revised 5.5% in January

·         February's jobs report presented yet another upside surprise to investors, and marked a fourteenth consecutive month of payroll growth.

·         5.8% wage growth is a wage cut if inflation is creeping up above 7%?

RegMed Investors’ (RMi) closing bell: “a worried sector, downtrodden by war anxieties. The gene editing patent reversal rewrites the genes of CRISPR's commercial and share pricing futures” … https://www.regmedinvestors.com/articles/12326

Ebb and flow –

·         March 1 – 2 negative and 1 positive closes

·         February stats: 11 negative, 8 positive closes and 1 holiday

·         January stats: 1 holiday, 1 neutral, 13 negative and 6 positive closes

Research Notes:

RegMed/Cell and Gene Therapy Earnings Scorecard Q4/21 and FY21 Results … https://www.regmedinvestors.com/articles/11628 ... Cellectis SA (CLLS) added - 21 total to date

The Biostage (OTC: QB: BSTG) Chronicles: Who, What, When, Where, Why and one H (HOW) … https://www.regmedinvestors.com/articles/12306

UC Berkeley loses CRISPR patent case, invalidating licenses it granted gene-editing companies https://www.regmedinvestors.com/articles/12320 - added commentary

Companies in my headlights – It’s your decision; I provide ideas and context:

SELL into Strength:

BioLife Solutions (BLFS) closed up +$0.55 after Wednesday’s +$0.44 after Tuesday’s +$0.21 with a positive +$1.00 or +4.05% pre-open indication,

BUY:

Cellectis SA (CLLS) closed down -$0.36 after Wednesday’s -$0.18 with a positive +$0.05 or +1.32% and earnings release,

Global Blood Therapeutics (GBT) closed down -$0.45 with a positive pre-open indication of +$0.51 or +1.79%

Intellia Therapeutics (NTLA -$13.42 after Wednesday’s +$4.54, Tuesday’s -$19.00, Monday’s +$2.49 and last Friday’s +$8.90) with a positive pre-open indication +$0.99 or +1.39%

Maintaining SELL:

Beam Therapeutics (BEAM -$6.40 after Wednesday’s +$0.70, Tuesday’s -$4.85 and Monday’s -$3.60) with a pre-open indication -$1.80 or -2.65%

Editas Medicine (EDIT -$0.41 after Wednesday’s -$0.34, Tuesday’s +$0.37 after Monday’s $0.22) with a pre-open indication -$0.11 or -0.66%

CRISPR Therapeutics (CRSP -$4.59 after Wednesday’s +$1.34, Tuesday’s -$3.93 and Monday’s +$1.64 after last Friday’s +$2.57) with a pre-open indication -$0.42 or -0.78%

Pimp/Pump and Promote:

Biostage (OTCQB: BSTG) closed up +$0.25 with 487 shares traded after Wednesday’s +$0.34 with 649 shares traded, Tuesday’s -$0.04 with 4,359 shares traded, Monday’s +$0.37 with 687 shares traded after last Friday’s flat with 70 shares traded …

• WHO is BUYING these shares of a company with a 3-year-old IND, NO clinical trial initiation, a terminal death lawsuit overhang and a dwindling cash position?
• Also, by use of the pump/promote process; is BSTG preparing to register the outstanding private placement (PP) shares for a reverse to initiate an offering - they’re NOT going ANYWHERE without a cash inflow.

The BOTTOM LINE: Another negative close Thursday – that’s two (2) for this new month of March.

The downside risks remain high on Friday.

There's still nothing wrong with selling into strength or even being in cash.

Earnings’ reporting on the horizon:

·         Athersys (ATHX), Tuesday, 3/15

·         Cellectis SA (CLLS) Thursday, 3/22

Investors should focus on forward-looking guidance, last year’s operating losses i.e., spending and cash positions or runways!

RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.

WHY do I keep reporting on Biostage (BSTG): I WAS there to experience what occurred and saw the decay of transparency and more; it takes courage, resolve and patience to stay the course of asking the questions without response!

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider their investment objectives.

Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in FATE, CRS, securities referred to in this publication.